🟡 Preliminary Evidence
Fresenius Kabi, an operating company of the Fresenius Group, has issued a voluntary nationwide recall of one lot of Morphine Sulfate Injection USP in Simplist® prefilled syringes due to a labeling mix-up that could compromise patient safety. According to the US Food and Drug Administration (FDA), the recalled product carries the potential for serious medication errors if dispensed or administered without verification. The recall was announced on August 4, 2026, and affects prefilled syringes labeled as Morphine 2 mg/1 mL that may contain a different product.
Key takeaways
- One lot of Morphine Sulfate Injection USP prefilled syringes recalled nationwide due to labeling discrepancy
- The mislabeled product poses risk of incorrect drug administration if label is not verified before dispensing
- Fresenius Kabi initiated the recall voluntarily; FDA supervision of recall distribution ongoing
- Healthcare facilities and pharmacies urged to verify all morphine products before patient administration
Labeling error creates medication safety risk
The recalled lot involves prefilled syringes with Simplist® technology, which are designed to improve medication safety through pre-filled, single-dose delivery. In this instance, the labeling system failed—the syringe labeled as containing Morphine 2 mg/1 mL may actually contain a different medication or concentration, creating the potential for serious harm if not caught during the verification process.
Fresenius Kabi did not specify the alternative substance or concentration in the mislabeled syringes in the public recall announcement, though the company confirmed the discrepancy was identified during quality control procedures. This suggests the error was caught before widespread distribution, reducing but not eliminating patient exposure risk.
Medication recall risks by error type
Common causes of US pharmaceutical recalls, 2020–2025
Source: US FDA Enforcement Reports, 2020–2025 | Georgian Medical Journal News
FDA oversight and distribution control
The FDA’s Center for Drug Evaluation and Research (CDER) is overseeing the recall distribution and verification process. Healthcare institutions that received the affected lot—identified by its specific lot number in Fresenius Kabi’s official recall notice—are required to segregate the product and prevent dispensing until verification is complete.
Pharmacists and nurses are instructed to verify the actual contents of any recalled Morphine Sulfate Injection USP prefilled syringes against the original prescription before administration. This secondary verification step, while standard practice, becomes critical in recalls involving labeling errors where the visible label cannot be trusted.
Clinical implications for acute and chronic pain management
Morphine sulfate is a cornerstone opioid analgesic used in hospitals, hospices, and outpatient pain management across the United States. A labeling error affecting this widely used drug increases the risk of medication administration errors (MAEs) in busy clinical environments where time pressure may lead staff to rely on label information without additional verification.
According to the Joint Commission National Patient Safety Goals, medication reconciliation and verification represent critical safeguards against such errors. This recall underscores the importance of redundant safety checks, particularly for high-risk drugs like opioids where dosing errors can result in overdose, respiratory depression, or other serious adverse events.
Labeling and packaging errors account for the largest category of pharmaceutical recalls in the United States, and morphine products are frequent subjects of FDA safety actions due to their narrow therapeutic window.
— US FDA Enforcement Reports, 2020–2025
What this means
Fresenius Kabi has committed to working with the FDA’s Office of Pharmaceutical Quality to prevent similar labeling errors in future production runs. Healthcare facilities reporting any adverse events or suspected medication errors related to this recall are encouraged to contact the FDA’s MedWatch program directly.
This recall represents one of hundreds of pharmaceutical safety actions initiated annually in the United States. For a comprehensive list of current recalls and safety alerts affecting morphine and other opioid products, healthcare professionals should regularly consult the FDA’s official recalls database and subscribe to automated safety notifications through their institutional pharmacy networks.
Source: Fresenius Kabi Issues Voluntary Nationwide Recall of One Lot of Morphine Sulfate Injection, USP in Simplist® Prefilled Syringe Due to Labeling Mix-up, FDA, August 4, 2026
Was this article helpful?
Related Coverage
